000			02888nam a22003257a 4500
001			CUHAS/BP/3000213/T/14
003			CUHAS/BP/3000213/T/14
005			20240305193843.0
008			210809b |||||||| |||| 00| 0 eng d
028			_bWurzburg Road 35, BMC Premises, Post Code: 33102:
028			_b P. O. Box 1464, Mwanza – Tanzania:
028			_bPhone: +255 28 298 3384:
028			_bFax: +255 28 298 3386:
028			_bEmail: vc@bugando.ac.tz :
028			_bwww.bugando.ac.tz
035			_a CUHAS/BP/3000213/T/14
040			_bEnglish _cDDC
041			_aEnglish
041			_aKiswahili
100			_a Paul, Tiberias _d CUHAS/BP/3000213/T/14 _920962
245			_a Utilization Outcomes of Magnesium Sulphate in the Management of Severe Pre-Eclampsia and Eclampsia at Bugando Medical Centre Maternity Ward
260			_aMwanza, Tanzania: _bCatholic University of Health and Allied Sciences [CUHAS – Bugando] : _c©2019
300			_axii; 28 Pages
300			_aIncludes References
520			_aAbstract: Background: Eclampsia continues to be a major problem in developing countries such as Tanzania, contributing significantly to high maternal and perinatal morbidity and mortality. WHO recommend magnesium sulfate as the most effective anticonvulsants which is most effective drug of choice for prevention of seizures Methodology: A retrospective study was conducted at Bugando medical centre maternity ward, Nyamagana in Mwanza region, Tanzania to obtain data of pregnant women admitted at Bugando medical centre for the period between January 2015 to December 2018. Study population was 340 pregnant women files in which random sampling method was used. The collected was analyzed by using SPSS version 20. Results and discussion: The average of participants was 25 years, 199 (58.5%) diagnosed with severe pre-eclampsia and 141 (41.4%) with eclampsia of which 330 (97.1%) were managed with magnesium sulphate, 6 (2.0%) Diazepam and 4 (0.9%) other anticonvulsants, 90% the outcome were alive and 7% motility was recorded. However, the mortality was very high compared to United States of America 0.5%. The high maternal mortality from complications of eclampsia is attributed to the limited capability to manage such complications in a low resource setting. Conclusion and recommendation: Magnesium sulphate is recommend by WHO to treat severe pre-eclampsia and eclampsia. The drug is cheap and relatively easy to produce, and so making it readily available for the care of women with eclampsia in both high-income and low-to-middle-income countries should be high priority. The government train more health professional to increase the work force in treatment of seizures in pregnant women.
600			_xPharmacy
600			_xObstetrics and Gynecology
700			_a Chibwe, Elieza _920637
942			_2ddc _cCR
999			_c20954 _d20954